• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·MRK
Held by 3 Gurus
Share

Merck & Co., Inc. Stocks

$ 139.54Last Updated 05.10.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

$ 356.40B

$ 139.54
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.1%

Change

-0.11%

Fund

CITADEL ADVISORS LLC

Steven Cohen

Portfolio Weight (%)

0.1%

Change

-0.10%

Fund

Point72 Asset Management, L.P.

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.02%

Fund

Bridgewater Associates

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.1%-0.11%
Steven CohenPoint72 Asset Management, L.P.0.1%-0.10%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.02%

Latest news

19.08.2026 18:10

Moderna announced the success of its experimental cancer vaccine. Its stock soared 120%.

22.04.2026 15:15

Morning in New York: trading will go without sharp movements

26.03.2026 17:11

Merck to buy mid-cap biotech Terns, but William Blair thinks the price tag is low

07.03.2026 04:15

'Most defensive sector': UBS names stocks that can 'safely survive war'

04.02.2026 15:45

Morning in New York: investors in search of a foothold

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of MRK is 162 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

09.10.2026 17:48

Data center optics are sold out for the next two years — Lumentum. Who else is seeing gains?

09.10.2026 17:26

Deeply Unpopular Stocks: Strategist Recommends Stocks to Ride Out the Sell-Off

09.10.2026 17:15

Shares of biotech company Pacira soared 44%: the maker of "Viagra" is set to acquire it

09.10.2026 16:48

The crisis in France could affect other countries. Which bonds are investors watching?

09.10.2026 16:34

Exxon Has Blocked a Settlement Agreement on the Kashagan Environmental Fine – Media Reports

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026